This retrospective study reports the data of sofosbuvir-based anti-hepatitis C virus treatment in 24 candidates and 24 recipients of liver transplantation coinfected with human immunodeficiency virus. Sustained virologic response was cumulatively 85% (90% and 100% in those treated with optimal schedules pre- and posttransplant, respectively).
This retrospective study reports the data of sofosbuvir-based anti-hepatitis C virus treatment in 24 candidates and 24 recipients of liver transplantation coinfected with human immunodeficiency virus. Sustained virologic response was cumulatively 85% (90% and 100% in those treated with optimal schedules pre- and posttransplant, respectively).
Successful Pre- and Posttransplant Sofosbuvir-Based Anti-Hepatitis C Virus Treatment in Persons Living With Human Immunodeficiency Virus Infection / Guaraldi, Giovanni; Rossotti, Roberto; Verucchi, Gabriella; Tavio, Marcello; Pasulo, Luisa; Beghetto, Barbara; Dolci, Giovanni; Nardini, Giulia; Badia, Lorenzo; Magliano, Anna; Moioli, Maria Cristina; Puoti, Massimo. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - 4:2(2017), pp. 1-5. [10.1093/ofid/ofx065]
Successful Pre- and Posttransplant Sofosbuvir-Based Anti-Hepatitis C Virus Treatment in Persons Living With Human Immunodeficiency Virus Infection
GUARALDI, Giovanni;BEGHETTO, Barbara;DOLCI, GIOVANNI;NARDINI, Giulia;
2017
Abstract
This retrospective study reports the data of sofosbuvir-based anti-hepatitis C virus treatment in 24 candidates and 24 recipients of liver transplantation coinfected with human immunodeficiency virus. Sustained virologic response was cumulatively 85% (90% and 100% in those treated with optimal schedules pre- and posttransplant, respectively).
| File | Dimensione | Formato | |
|---|---|---|---|
|
2017_Successful Pre and Posttransplant.pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
180.19 kB
Formato
Adobe PDF
|
180.19 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
